5 Biopharma Trends to Watch in 2019
Merck takes a back seat on CAR-T, handing assets to Intrexon
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape. Κάντε like … Continue Reading Ash 2018 preview – blood cancers offer biotech a chance at redemption
CAR-T Promise for Patients with Solid Tumors
Intellia’s CRISPR Trial Delay Raises Questions About Immune Responses
Focused on Off-The-Shelf CAR-T, Allogene Therapeutics Hits the Nasdaq at $18 per Share
Celyad has received FDA approval to start clinical trials for its CAR-T cell therapy, which is engineered to avoid side effects associated with using donor cells for this kind of … Continue Reading Celyad’s Donor Cell CAR-T Therapy Gets Closer to the Clinic
CAR-T companies are on the rise, supported by growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah and Yescarta), and major acquisitions within … Continue Reading CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project (“HGP”), this precise and personal approach to medicine is an emerging discipline with enormous disruptive … Continue Reading Genomic Medicine: Catch The Gene Therapy Wave
Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are … Continue Reading It’s Blood Cancer Day, how is Biotech fixing it?
Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno … Continue Reading What do the CAR-T Patient Deaths Mean for the Future of the Field?
CAR-T therapy has been hailed as a cure for cancer, but what really is this “miraculous technology” and what can we actually expect from it? The field of immuno-oncology is booming with … Continue Reading A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology Reviews